ASCO-GU – another strike against Cabometyx
A triplet did worse than control in first-line kidney cancer.
ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
Triple meeting 2024 – casdatifan looks like Welireg
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
ESMO 2024 – NiKang’s case for a better Welireg
The company’s HIF-2α inhibitor impresses on efficacy, but its long half life raises eyebrows.
Arcus makes its HIF2α pitch
After living in the shadow of Arcus’s TIGIT project, casdatifan might soon come into its own.
Novartis calls time on TIM-3 and HIF2α
The company’s move could be a warning for rivals including GSK, AstraZeneca and Incyte.
ASCO-GU – Keytruda strengthens its kidney cancer monopoly
Merck adds an overall survival benefit while Bristol sinks further.
